Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 222Carboplatin 215Cisplatin 203Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 114Cyclophosphamide 102Pemetrexed 100Dexamethasone 100Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 94Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 68durvalumab 65Lenalidomide 64Radiation 62atezolizumab 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Sigmoidoscopy × 1 year × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡